Related Experiment Video
Updated: May 1, 2026
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
Published on: January 21, 2020
Short-term treatment with parecoxib for complex regional pain syndrome: a randomized, placebo-controlled double-blind
Anna J Breuer1, Tina Mainka, Nora Hansel
1Department of Pain Medicine, Berufsgenossenschaftliches Universitatsklinikum Bergmannsheil GmbH Bochum, Ruhr University Bochum, Germany.
Background:
Complex regional pain syndrome (CRPS) is characterized by signs and symptoms of peripheral inflammation, which leads to peripheral neural sensitization associated most frequently (in about 70%) with blunt pressure hyperalgesia. Therefore, we hypothesized that treatment of CRPS patients with a selective COX-2-inhibitor would alleviate the abnormally low pressure pain threshold (PPT) and reduce pain intensity and edema.
Methods:
Twenty patients with CRPS type I (n = 16) and II of the upper limb and abnormally low PPT were double-blind randomised into 2 groups of 10 patients each to receive a 2-day intravenous treatment of either 80 mg parecoxib per day (group I) or placebo (NaCl 0.9%, group II). Standardized quantitative sensory testing (QST) using the DFNS protocol was performed before and after treatment. Pain intensity (NRS 0 - 10); circumferences of the fingers II, IV, and V (mm); PPT (kPa, thenar/hypothenar); and adverse events were recorded daily.
Statistics:
Wilcoxon-test, Mann-Whitney-U-test, Friedman-test, Fisher-test, significance level: P < 0.05.
Study Design:
Proof of concept trial performed in randomized, placebo-controlled, double blind style .
Setting:
Pain Management Center in Germany.
Results:
There were no group differences in PTT or other QST parameters. After treatment, PPT decreased insignificantly in group I (median [range]; before: 224.0 [121.0 - 52937] kPa, afterwards: 186.4 [101.4 - 526.5] kPa) and increased insignificantly in group II (before: 207.6 [170.0 - 320.5] kPa; afterwards: 235.4 [163.5 - 349.9] kPa). Pain scores and finger circumferences remained unchanged in both groups.
Limitations:
Due to difficulty in recruitment the trial was closed after inclusion of 20 patients.
Conclusion:
In the present proof-of-concept trial, short-term treatment with the selective COX-2-inhibitor parecoxib influenced neither PPT nor edema or pain. COX-2 might be less important than previously assumed. However, the results are limited due to the small number of patients, short-term treatment, and focus on the PPT, which could have led to false negative results of the present study and covered the expected therapeutic effect.
